Drug Trial Radar · NCT03321955
Ziconotide as First-Line IDT
Last checked: Nov 20, 2026Latest source record: Jan 12, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
13
Actual
Start
Nov 3, 2016
Primary completion
Aug 30, 2020
Study completion Dec 30, 2020
Sponsor
- Lead sponsor
- Albany Medical CollegeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 26, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to prospectively examine outcomes in 12 patients using ziconotide Intrathecal Drug Therapy(IDT) as first-line monotherapy with the use of an algorithm of slow titration for dosing. The use of Prialt has demonstrated fewer and less serious associated adverse effects as compared to IDT morphine, especially when titrated slowly. We will use an average Numerical Rating Scale as our primary outcome and the Oswestry Disability Index(ODI), Beck Depression Inventory (BDI), Pain Catastrophizing Scale (PCS), Clinical Global Impression of Change Scale including binary satisfaction measures(CGIC), Lawton-Brody Instrumental Activities of Daily Living(IADL) and Short Form-36 as secondary outcome measures.
Conditions
- Neuropathic Pain
Interventions
Ziconotide 100 MCG(microgram)/ML Intrathecal SolutionDrug
Initial dose at time of the implant will be 1.2 mcg/day with dose increases of no more the .4 mcg/day planned for 3, 6, 8, 9, 10, 12 weeks and 4, 5, 6 and 12 months.
Quantitative sensory testingDiagnostic test
Quantitative sensory testing will be done using different types of sensory stimulation to objectively quantify sensation and pain tolerance. VonFrey fibers of various widths are used to detect sensation, a Neuropen pin prick iutilized to detect pain, along with a tuning fork to measure vibrationand a pressure guage to measure pressure felt on the skin. Cold/hot sensation is tested with Medoc Pathway system to quantitatively measure the temperature felt by patients to be done at baseline, 6 months and 12 months,
Serum markers: Interleukin-1, Interleukin-6, and tumor necrosis factorDiagnostic test
Increases in these biomarkers indicate nerve pain as they are released from macrophages in patients with damaged nerves.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Numerical Rating Scale (NRS)Time frame: Baseline, 3, 4, 6, 8, 9, 10, 12 week and 4, 5, 6 and 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Albany Medical College
Albany, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.